424 related articles for article (PubMed ID: 17708420)
21. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
[TBL] [Abstract][Full Text] [Related]
22.
Bosè F; Renna LV; Fossati B; Arpa G; Labate V; Milani V; Botta A; Micaglio E; Meola G; Cardani R
Front Neurol; 2019; 10():992. PubMed ID: 31611837
[TBL] [Abstract][Full Text] [Related]
23. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1.
Ward AJ; Rimer M; Killian JM; Dowling JJ; Cooper TA
Hum Mol Genet; 2010 Sep; 19(18):3614-22. PubMed ID: 20603324
[TBL] [Abstract][Full Text] [Related]
24. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice.
Oana K; Oma Y; Suo S; Takahashi MP; Nishino I; Takeda S; Ishiura S
Sci Rep; 2013; 3():2142. PubMed ID: 23828222
[TBL] [Abstract][Full Text] [Related]
25. Progression of muscle histopathology but not of spliceopathy in myotonic dystrophy type 2.
Cardani R; Giagnacovo M; Rossi G; Renna LV; Bugiardini E; Pizzamiglio C; Botta A; Meola G
Neuromuscul Disord; 2014 Dec; 24(12):1042-53. PubMed ID: 25139674
[TBL] [Abstract][Full Text] [Related]
26. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
Ranum LP; Day JW
Curr Neurol Neurosci Rep; 2002 Sep; 2(5):465-70. PubMed ID: 12169228
[TBL] [Abstract][Full Text] [Related]
27. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
[TBL] [Abstract][Full Text] [Related]
28. Pathogenic mechanisms of myotonic dystrophy.
Lee JE; Cooper TA
Biochem Soc Trans; 2009 Dec; 37(Pt 6):1281-6. PubMed ID: 19909263
[TBL] [Abstract][Full Text] [Related]
29. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.
Bachinski LL; Baggerly KA; Neubauer VL; Nixon TJ; Raheem O; Sirito M; Unruh AK; Zhang J; Nagarajan L; Timchenko LT; Bassez G; Eymard B; Gamez J; Ashizawa T; Mendell JR; Udd B; Krahe R
Neuromuscul Disord; 2014 Mar; 24(3):227-40. PubMed ID: 24332166
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Targeting of the GSK3β-CUGBP1 Pathway in Myotonic Dystrophy.
Lutz M; Levanti M; Karns R; Gourdon G; Lindquist D; Timchenko NA; Timchenko L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445828
[TBL] [Abstract][Full Text] [Related]
31. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2.
Mankodi A; Urbinati CR; Yuan QP; Moxley RT; Sansone V; Krym M; Henderson D; Schalling M; Swanson MS; Thornton CA
Hum Mol Genet; 2001 Sep; 10(19):2165-70. PubMed ID: 11590133
[TBL] [Abstract][Full Text] [Related]
32. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
Dansithong W; Paul S; Comai L; Reddy S
J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
[TBL] [Abstract][Full Text] [Related]
33. Myotonic dystrophy types 1 and 2.
Ashizawa T; Sarkar PS
Handb Clin Neurol; 2011; 101():193-237. PubMed ID: 21496635
[TBL] [Abstract][Full Text] [Related]
34. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
[TBL] [Abstract][Full Text] [Related]
35. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies.
Meola G
Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843
[TBL] [Abstract][Full Text] [Related]
36. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.
Fugier C; Klein AF; Hammer C; Vassilopoulos S; Ivarsson Y; Toussaint A; Tosch V; Vignaud A; Ferry A; Messaddeq N; Kokunai Y; Tsuburaya R; de la Grange P; Dembele D; Francois V; Precigout G; Boulade-Ladame C; Hummel MC; Lopez de Munain A; Sergeant N; Laquerrière A; Thibault C; Deryckere F; Auboeuf D; Garcia L; Zimmermann P; Udd B; Schoser B; Takahashi MP; Nishino I; Bassez G; Laporte J; Furling D; Charlet-Berguerand N
Nat Med; 2011 Jun; 17(6):720-5. PubMed ID: 21623381
[TBL] [Abstract][Full Text] [Related]
37. Flies deficient in Muscleblind protein model features of myotonic dystrophy with altered splice forms of Z-band associated transcripts.
Machuca-Tzili L; Thorpe H; Robinson TE; Sewry C; Brook JD
Hum Genet; 2006 Nov; 120(4):487-99. PubMed ID: 16927100
[TBL] [Abstract][Full Text] [Related]
38. Zebrafish deficient for Muscleblind-like 2 exhibit features of myotonic dystrophy.
Machuca-Tzili LE; Buxton S; Thorpe A; Timson CM; Wigmore P; Luther PK; Brook JD
Dis Model Mech; 2011 May; 4(3):381-92. PubMed ID: 21303839
[TBL] [Abstract][Full Text] [Related]
39. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1.
Koshelev M; Sarma S; Price RE; Wehrens XH; Cooper TA
Hum Mol Genet; 2010 Mar; 19(6):1066-75. PubMed ID: 20051426
[TBL] [Abstract][Full Text] [Related]
40. Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1.
Lueck JD; Lungu C; Mankodi A; Osborne RJ; Welle SL; Dirksen RT; Thornton CA
Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1291-7. PubMed ID: 17135300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
